Los Angeles, CA—Researchers from the Palm Beach Research Center in Florida have compiled compelling data on the effects of a proprietary squid-derived chondroitin E ingredient (IncaCartilago from OptiPure/Kenko International, based here) on bone health.
The researchers conducted a three-month trial in which 52 people with osteoarthritis (OA) of the knee took a placebo or chondroitin E (250 mg daily). Individuals were allowed to take acetaminophen for pain, but not within 24 hours of an evaluation visit. Pain, stiffness and functionality were assessed using several measurements including WOMAC, Lequesne Index VAS and Physician/Subject Global Assessments; they also kept diaries and took Dexa Scans before and at the end of the trial. Overall, the supplement was significantly more effective at reducing OA symptoms than the placebo. In all categories, the supplement improved subjects’ discomfort, inflexibility and functionality.
Perhaps even more significant, Dexa Scans revealed a notable increase in bone density in the lumbar vertibrae L1–L4 area (using Z-Score) compared to the placebo. The mean change from baseline in the supplement group was 0.001, where as the placebo group experienced density declines (–0.183 on average).
The timeframe in which improvements were seen is noteworthy, says Ron Udell, president and CEO of Kenko International Inc. (OptiPure Division). “The statistical significance is the strongest we’ve ever seen for enhancing bone density in a 90-day trial using Dexa Scan, which is very objective…the study is very strong,” says Udell.
Udell feels the results of the Dexa Scans set apart the ingredient. “There’s no commercially available bone density- enhancing product where you’ll see bone density change like you see here,” he states, noting the company will conduct additional studies on squid-derived chondroitin E for bone health in the future.
Published in WholeFoods Magazine, April 2013 (online 2/21/13, updated 3/15/13)